{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:40:22Z","timestamp":1778539222154,"version":"3.51.4"},"reference-count":150,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020555","name":"Ospedale Pediatrico Bambino Ges\u00f9 IRCCS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020555","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.vaccine.2025.126853","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T17:21:10Z","timestamp":1739380870000},"page":"126853","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Shielding the immunocompromised: COVID-19 prevention strategies for patients with primary and secondary immunodeficiencies"],"prefix":"10.1016","volume":"51","author":[{"given":"Giulio","family":"Olivieri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donato","family":"Amodio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma Concetta","family":"Manno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Santilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Cotugno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Palma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.126853_bb0005","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13511","article-title":"American Society of Transplantation infectious diseases community of practice. RNA respiratory viral infections in solid organ transplant recipients: guidelines from the American society of transplantation infectious diseases community of practice","volume":"33","author":"Manuel","year":"2019","journal-title":"Clin Transpl"},{"key":"10.1016\/j.vaccine.2025.126853_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101965","article-title":"Vaccines and therapeutics for immunocompromised patients with COVID-19","volume":"59","author":"Shoham","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.vaccine.2025.126853_bb0015","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abb1662","article-title":"Human inborn errors of immunity: an expanding universe","volume":"5","author":"Notarangelo","year":"2020","journal-title":"Sci Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0020","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jama.2023.28019","article-title":"Prevalence of immunosuppression among US adults","volume":"331","author":"Martinson","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2025.126853_bb0025","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1038\/s41591-023-02414-4","article-title":"SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease","volume":"29","author":"Barnes","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2025.126853_bb0030","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s10875-022-01231-7","article-title":"SARS-CoV-2 vaccine responses in individuals with antibody deficiency: findings from the COV-AD study","volume":"42","author":"Shields","year":"2022","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.889138","article-title":"SARS-CoV-2-mRNA booster vaccination reverses non-responsiveness and early antibody waning in immunocompromised patients - a phase four study comparing immune responses in patients with solid cancers, multiple myeloma and inflammatory bowel disease","volume":"13","author":"Wagner","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0040","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1093\/cid\/ciac408","article-title":"Perinatally human immunodeficiency virus-infected adolescents and young adults demonstrate distinct BNT162b2 messenger RNA coronavirus disease 2019 vaccine immunogenicity","volume":"75","author":"Morrocchi","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126853_bb0045","doi-asserted-by":"crossref","first-page":"e630","DOI":"10.1093\/cid\/ciac103","article-title":"Prospective evaluation of coronavirus disease 2019 (COVID-19) vaccine responses across a broad Spectrum of immunocompromising conditions: the COVID-19 vaccination in the immunocompromised study (COVICS)","volume":"75","author":"Haidar","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126853_bb0050","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1016\/S2665-9913(24)00065-1","article-title":"Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial","volume":"6","author":"Goodyear","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0055","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3390\/microorganisms12010089","article-title":"Vaccinating against a novel pathogen: a critical review of COVID-19 vaccine effectiveness evidence","volume":"12","author":"Black","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.vaccine.2025.126853_bb0060","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.126853_bb0065","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 - preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.126853_bb0070","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.anai.2022.06.009","article-title":"Immunizing the imperfect immune system: coronavirus disease 2019 vaccination in patients with inborn errors of immunity","volume":"129","author":"Durkee-Shock","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0075","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.cmi.2022.05.005","article-title":"Immunocompromised patients have been neglected in COVID-19 trials: a call for action","volume":"28","author":"Tr\u00f8seid","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2025.126853_bb0080","first-page":"0","article-title":"COVID-19 and inborn errors of immunity","volume":"37","author":"Delmonte","year":"2022","journal-title":"Physiology (Bethesda)"},{"key":"10.1016\/j.vaccine.2025.126853_bb0085","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10875-022-01382-7","article-title":"COVID-19 vaccination responses with different vaccine platforms in patients with inborn errors of immunity","volume":"43","author":"Erra","year":"2023","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0090","article-title":"Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis","volume":"376","author":"Lee","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2025.126853_bb0095","article-title":"Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: a retrospective cohort study","volume":"9","author":"Tartof","year":"2022","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/j.vaccine.2025.126853_bb0100","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/S2213-2600(22)00170-9","article-title":"Immunocompromise and durability of BNT162b2 vaccine against severe outcomes due to omicron and delta variants","volume":"10","author":"Tartof","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.vaccine.2025.126853_bb0105","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.anai.2022.06.009","article-title":"Immunizing the imperfect immune system","volume":"129","author":"Durkee-Shock","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0110","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/j.immuni.2022.07.005","article-title":"Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination","volume":"55","author":"Gao","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2025.126853_bb0115","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3390\/vaccines10071109","article-title":"Evaluation of safety and immunogenicity of BNT162B2 mRNA COVID-19 vaccine in IBD pediatric population with distinct immune suppressive regimens","volume":"10","author":"Cotugno","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.126853_bb0120","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1097\/TP.0000000000003999","article-title":"BNT162B2 mRNA COVID-19 vaccine in heart and lung transplanted young adults: is an alternative SARS-CoV-2 immune response surveillance needed?","volume":"106","author":"Cotugno","year":"2022","journal-title":"Transplantation"},{"key":"10.1016\/j.vaccine.2025.126853_bb0125","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/jamainternmed.2021.7024","article-title":"Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US","volume":"182","author":"Sun","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.vaccine.2025.126853_bb0130","doi-asserted-by":"crossref","first-page":"19","DOI":"10.15585\/mmwr.mm7101a4","article-title":"Risk factors for severe COVID-19 outcomes among persons aged \u226518 years who completed a primary COVID-19 vaccination series - 465 health care facilities, United States, December 2020-October 2021","volume":"71","author":"Yek","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2025.126853_bb0135","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jinf.2023.01.024","article-title":"Characteristics and risk factors of prolonged viable virus shedding in immunocompromised patients with COVID-19: a prospective cohort study","volume":"86","author":"Kang","year":"2023","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2025.126853_bb0140","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4049\/jimmunol.2300190","article-title":"Third and fourth vaccine doses broaden and prolong immunity to SARS-CoV-2 in adult patients with immune-mediated inflammatory diseases","volume":"211","author":"Cheung","year":"2023","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0145","article-title":"COVID-19 hospitalisations in immunocompromised individuals in the omicron era: a population-based observational study using surveillance data in British Columbia","volume":"20","author":"Bahremand","year":"2023","journal-title":"Canada Lancet Reg Health Am"},{"key":"10.1016\/j.vaccine.2025.126853_bb0150","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(22)01656-7","article-title":"Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales","volume":"400","author":"Agrawal","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.126853_bb0155","article-title":"Impact of COVID-19 on immunocompromised populations during the omicron era: insights from the observational population-based INFORM study","volume":"35","author":"Evans","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.vaccine.2025.126853_bb0160","doi-asserted-by":"crossref","first-page":"878","DOI":"10.15585\/mmwr.mm7127a3","article-title":"Factors associated with severe outcomes among immunocompromised adults hospitalized for COVID-19 - COVID-NET, 10 states, march 2020-February 2022","volume":"71","author":"Singson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2025.126853_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004086","article-title":"Outcome of COVID-19 in hospitalised immunocompromised patients: an analysis of the WHO ISARIC CCP-UK prospective cohort study","volume":"20","author":"Turtle","year":"2023","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2025.126853_bb0170","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s12325-023-02754-0","article-title":"Assessing the burden and cost of COVID-19 across variants in commercially insured immunocompromised populations in the United States: updated results and trends from the ongoing EPOCH-US study","volume":"41","author":"Ketkar","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.vaccine.2025.126853_bb0175","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.1259","article-title":"Immunocompromised individuals are at increased risk of COVID-19 breakthrough infection, hospitalization, and death in the post-vaccination era: a systematic review","volume":"12","author":"Bytyci","year":"2024","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.vaccine.2025.126853_bb0180","doi-asserted-by":"crossref","first-page":"128","DOI":"10.15585\/mmwr.mm7205e3","article-title":"Information for persons who are immunocompromised regarding prevention and treatment of SARS-CoV-2 infection in the context of currently circulating omicron sublineages - United States, january 2023","volume":"72","author":"Patel","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2025.126853_bb0185","doi-asserted-by":"crossref","first-page":"e461","DOI":"10.1016\/S2665-9913(23)00160-1","article-title":"Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from melody","volume":"5","author":"Pearce","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0190","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.jaip.2020.04.003","article-title":"Health-related quality of life in common variable immunodeficiency Italian patients switched to remote assistance during the COVID-19 pandemic","volume":"8","author":"Pulvirenti","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.vaccine.2025.126853_bb0195","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.puhe.2023.02.008","article-title":"Did the UK\u2019s public health shielding policy protect the clinically extremely vulnerable during the COVID-19 pandemic in Wales? Results of EVITE immunity, a linked data retrospective study","volume":"218","author":"Snooks","year":"2023","journal-title":"Public Health"},{"key":"10.1016\/j.vaccine.2025.126853_bb0200","article-title":"Impact of COVID-19 on immunocompromised populations during the omicron era: insights from the observational population-based INFORM study","volume":"35","author":"Evans","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.vaccine.2025.126853_bb0205","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/s41591-022-01780-9","article-title":"Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults","volume":"28","author":"Killingley","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2025.126853_bb0210","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2025.126853_bb0215","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41392-021-00481-y","article-title":"Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need","volume":"6","author":"Jin","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.vaccine.2025.126853_bb0220","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.cell.2020.12.015","article-title":"COVID-19-neutralizing antibodies predict disease severity and survival","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2025.126853_bb0225","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.984376","article-title":"Impact of vaccination on hospitalization and mortality from COVID-19 in patients with primary and secondary immunodeficiency: the United Kingdom experience","volume":"13","author":"Shields","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0230","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1136\/annrheumdis-2021-221922","article-title":"Postvaccination antibody titres predict protection against COVID-19 in patients with autoimmune diseases: survival analysis in a prospective cohort","volume":"81","author":"Ahmed","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2025.126853_bb0235","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1093\/ndt\/gfac016","article-title":"COVID-19 outbreak in vaccinated patients from a haemodialysis unit: antibody titres as a marker of protection from infection","volume":"37","author":"Boudhabhay","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.vaccine.2025.126853_bb0240","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1681\/ASN.2022010046","article-title":"The impact of vaccination on incidence and outcomes of SARS-CoV-2 infection in patients with kidney failure in Scotland","volume":"33","author":"Bell","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0245","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1136\/annrheumdis-2021-220272","article-title":"Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort","volume":"80","author":"Geisen","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2025.126853_bb0250","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study","volume":"80","author":"Furer","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2025.126853_bb0255","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41584-022-00755-x","article-title":"COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations","volume":"18","author":"Grainger","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0260","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1136\/annrheumdis-2021-220503","article-title":"Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2","volume":"80","author":"Braun-Moscovici","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2025.126853_bb0265","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1001\/jama.2021.7489","article-title":"Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients","volume":"325","author":"Boyarsky","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2025.126853_bb0270","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ejca.2021.10.014","article-title":"Immunogenicity and risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection after coronavirus disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis","volume":"160","author":"Becerril-Gaitan","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.vaccine.2025.126853_bb0275","doi-asserted-by":"crossref","first-page":"746","DOI":"10.4143\/crt.2022.1541","article-title":"Immunogenicity and safety of vaccines against coronavirus disease in actively treated patients with solid tumors: a prospective cohort study","volume":"55","author":"Baek","year":"2023","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.vaccine.2025.126853_bb0280","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.cmi.2021.09.036","article-title":"Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review","volume":"28","author":"Galmiche","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2025.126853_bb0285","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41541-024-00866-4","article-title":"COVID-19 vaccination induces distinct T-cell responses in pediatric solid organ transplant recipients and immunocompetent children","volume":"9","author":"Roznik","year":"2024","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2025.126853_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577746","article-title":"Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: up to 6 months cross-sectional study","volume":"361","author":"Achiron","year":"2021","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0295","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1136\/gutjnl-2021-324789","article-title":"Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD","volume":"70","author":"Kennedy","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.vaccine.2025.126853_bb0300","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/annrheumdis-2021-221575","article-title":"Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations","volume":"81","author":"Kroon","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2025.126853_bb0305","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41584-023-00992-8","article-title":"Effect of DMARDs on the immunogenicity of vaccines","volume":"19","author":"van Sleen","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0310","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1016\/S2665-9913(22)00034-0","article-title":"Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study","volume":"4","author":"Wieske","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0315","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3899\/jrheum.170710","article-title":"A systematic review and metaanalysis of antirheumatic drugs and vaccine immunogenicity in rheumatoid arthritis","volume":"45","author":"Subesinghe","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0320","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41467-022-28517-z","article-title":"Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab","volume":"13","author":"Lin","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2025.126853_bb0325","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.1002\/jmv.28063","article-title":"The long term vaccine-induced anti-SARS-CoV-2 immune response is impaired in quantity and quality under TNF\u03b1 blockade","volume":"94","author":"Geisen","year":"2022","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0330","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/ecco-jcc\/jjab147","article-title":"T cell response after SARS-CoV-2 vaccination in immunocompromised patients with inflammatory bowel disease","volume":"16","author":"Reuken","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.vaccine.2025.126853_bb0335","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1136\/annrheumdis-2021-220656","article-title":"High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases","volume":"80","author":"Ruddy","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2025.126853_bb0340","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2021.04.025","article-title":"Serologic response to messenger RNA coronavirus disease 2019 vaccines in inflammatory bowel disease patients receiving biologic therapies","volume":"161","author":"Wong","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.vaccine.2025.126853_bb0345","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1038\/s41591-021-01469-5","article-title":"Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial","volume":"27","author":"Medeiros-Ribeiro","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2025.126853_bb0350","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/annrheumdis-2021-221244","article-title":"Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases","volume":"80","author":"Friedman","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2025.126853_bb0355","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/s41591-021-01507-2","article-title":"Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy","volume":"27","author":"Apostolidis","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2025.126853_bb0360","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002036","article-title":"Humoral and cellular immune responses on SARS-CoV-2 vaccines in patients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients","volume":"8","author":"Schietzel","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.vaccine.2025.126853_bb0365","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s41375-021-01418-8","article-title":"Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell non-Hodgkin\u2019s lymphomas","volume":"36","author":"Marchesi","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.vaccine.2025.126853_bb0370","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1001\/jamaneurol.2021.3599","article-title":"Humoral and T-cell response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated with Ocrelizumab","volume":"78","author":"Brill","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0375","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1136\/annrheumdis-2021-221554","article-title":"Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease","volume":"81","author":"Simon","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2025.126853_bb0380","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keac089","article-title":"Humoral and cellular response to COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases under real-life conditions","volume":"61","author":"Krasselt","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.vaccine.2025.126853_bb0385","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/rheumatology\/keac365","article-title":"Immunosuppressive treatments selectively affect the humoral and cellular response to SARS-CoV-2 in vaccinated patients with vasculitis","volume":"62","author":"Monti","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.vaccine.2025.126853_bb0390","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/s41467-022-28527-x","article-title":"Population antibody responses following COVID-19 vaccination in 212,102 individuals","volume":"13","author":"Ward","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2025.126853_bb0395","first-page":"1","article-title":"Behavior and fate of s-triazines in soils","volume":"8","author":"Harris","year":"1968","journal-title":"Adv Pest Control Res"},{"key":"10.1016\/j.vaccine.2025.126853_bb0400","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/S0140-6736(21)02096-1","article-title":"Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients","volume":"398","author":"Prendecki","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.126853_bb0405","article-title":"Comparison of immunogenicity and clinical effectiveness between BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines in people with end-stage kidney disease receiving haemodialysis: a prospective, observational cohort study","volume":"21","author":"Martin","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.vaccine.2025.126853_bb0410","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1136\/annrheumdis-2021-221145","article-title":"Antibody response to the Janssen\/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases","volume":"80","author":"Chiang","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2025.126853_bb0415","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.jhep.2021.08.008","article-title":"Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases","volume":"75","author":"Thuluvath","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0420","article-title":"Tfh cells and the germinal center are required for memory B cell formation & humoral immunity after ChAdOx1 nCoV-19 vaccination","volume":"3","author":"Foster","year":"2022","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.vaccine.2025.126853_bb0425","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abl5652","article-title":"High-affinity, neutralizing antibodies to SARS-CoV-2 can be made without T follicular helper cells","volume":"7","author":"Chen","year":"2022","journal-title":"Sci Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0430","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1097\/TP.0000000000004140","article-title":"A fourth dose of COVID-19 vaccine does not induce neutralization of the omicron variant among solid organ transplant recipients with suboptimal vaccine response","volume":"106","author":"Karaba","year":"2022","journal-title":"Transplantation"},{"key":"10.1016\/j.vaccine.2025.126853_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101642","article-title":"Immune responses following 3rd and 4th doses of heterologous and homologous COVID-19 vaccines in kidney transplant recipients","volume":"53","author":"Thomson","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.vaccine.2025.126853_bb0440","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1108546","article-title":"Humoral response after a fourth dose of SARS-CoV-2 vaccine in immunocompromised patients. Results of a systematic review","volume":"11","author":"Martinelli","year":"2023","journal-title":"Front Public Health"},{"key":"10.1016\/j.vaccine.2025.126853_bb0445","article-title":"Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform","volume":"379","author":"Zheng","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2025.126853_bb0450","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1097\/INF.0000000000003263","article-title":"Safety and tolerability of monoclonal antibody therapies for treatment of COVID-19 in pediatric patients","volume":"40","author":"Mak","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2025.126853_bb0455","first-page":"369","article-title":"Safety of monoclonal antibodies in children affected by SARS-CoV-2 infection","volume":"9","author":"Romani","year":"2022","journal-title":"Children (Basel)"},{"key":"10.1016\/j.vaccine.2025.126853_bb0460","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.720205","article-title":"SARS-CoV-2 spike protein-directed monoclonal antibodies may ameliorate COVID-19 complications in APECED patients","volume":"12","author":"Ferr\u00e9","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0465","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.cell.2021.02.035","article-title":"Extremely potent human monoclonal antibodies from COVID-19 convalescent patients","volume":"184","author":"Andreano","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2025.126853_bb0470","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41579-022-00809-7","article-title":"SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies","volume":"21","author":"Cox","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0475","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3390\/diseases10040118","article-title":"Efficacy and safety of tixagevimab\/cilgavimab to prevent COVID-19 (pre-exposure prophylaxis): a systematic review and Meta-analysis","volume":"10","author":"Alhumaid","year":"2022","journal-title":"Diseases"},{"key":"10.1016\/j.vaccine.2025.126853_bb0480","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40001-023-01549-x","article-title":"The efficacy of tixagevimab\/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis","volume":"29","author":"Glhoom","year":"2024","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.vaccine.2025.126853_bb0485","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2420","article-title":"Efficacy and safety of tixagevimab-cilgavimab as pre-exposure prophylaxis for COVID-19: a systematic review and meta-analysis","volume":"33","author":"Soeroto","year":"2023","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0490","first-page":"jiae306","article-title":"A robust SARS-CoV-2-specific T and B cell response is associated with early viral clearance in SARS-CoV-2 omicron-infected immunocompromised individuals","author":"Vergouwe","year":"2024","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126853_bb0495","doi-asserted-by":"crossref","first-page":"13272","DOI":"10.3389\/ti.2024.13272","article-title":"In vitro and in vivo neutralizing efficacy of monoclonal antibodies against Sars-Cov-2 variants in kidney transplant recipients","volume":"37","author":"Benotmane","year":"2024","journal-title":"Transpl Int"},{"key":"10.1016\/j.vaccine.2025.126853_bb0500","doi-asserted-by":"crossref","first-page":"e460","DOI":"10.1016\/S1473-3099(23)00575-3","article-title":"Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant","volume":"23","author":"Uriu","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126853_bb0505","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.cell.2022.12.018","article-title":"Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants","volume":"186","author":"Wang","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2025.126853_bb0510","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.cmi.2024.04.012","article-title":"An update on the anti-spike monoclonal antibody pipeline for SARS-CoV-2","volume":"30","author":"Focosi","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2025.126853_bb0515","series-title":"1355. The SARS-CoV-2 monoclonal antibody AZD3152 potently neutralizes historical and emerging variants and is being developed for the prevention and treatment of COVID-19 in high-risk individuals. Open forum infectious diseases","author":"Francica","year":"2023"},{"key":"10.1016\/j.vaccine.2025.126853_bb0520","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nbt.1601","article-title":"Enhanced antibody half-life improves in vivo activity","volume":"28","author":"Zalevsky","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0525","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1001\/jamaoncol.2021.1799","article-title":"Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19","volume":"7","author":"Thompson","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0530","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10875-021-01193-2","article-title":"Case series: convalescent plasma therapy for patients with COVID-19 and primary antibody deficiency","volume":"42","author":"Lang-Meli","year":"2022","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0535","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1016\/j.jaip.2021.04.017","article-title":"Clinical outcome, incidence, and SARS-CoV-2 infection-fatality rates in Italian patients with inborn errors of immunity","volume":"9","author":"Milito","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.vaccine.2025.126853_bb0540","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10875-020-00928-x","article-title":"Impact of SARS-CoV-2 pandemic on patients with primary immunodeficiency","volume":"41","author":"Delavari","year":"2021","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0545","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1093\/infdis\/jiad145","article-title":"SARS-CoV-2 infection and response to COVID-19 vaccination in patients with primary immunodeficiencies","volume":"228","author":"Paris","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126853_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2022.109097","article-title":"COVID-19-related health outcomes in people with primary immunodeficiency: a systematic review","volume":"243","author":"Drzymalla","year":"2022","journal-title":"Clin Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0555","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jinf.2021.11.005","article-title":"Immunocompromised children and young people are at no increased risk of severe COVID-19","volume":"84","author":"Chappell","year":"2022","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2025.126853_bb0560","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/ACI.0000000000000792","article-title":"COVID-19 and X-linked agammaglobulinemia (XLA) - insights from a monogenic antibody deficiency","volume":"21","author":"Ponsford","year":"2021","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0565","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.994253","article-title":"Outcome of SARS-CoV-2 infection among patients with common variable immunodeficiency and a matched control group: a Danish nationwide cohort study","volume":"13","author":"Katzenstein","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0570","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaci.2020.12.620","article-title":"COVID-19 in patients with primary and secondary immunodeficiency: the United Kingdom experience","volume":"147","author":"Shields","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0575","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jaci.2020.09.010","article-title":"Coronavirus disease 2019 in patients with inborn errors of immunity: an international study","volume":"147","author":"Meyts","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0580","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2025.126853_bb0585","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20210554","article-title":"Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1","volume":"218","author":"Bastard","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2025.126853_bb0590","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.jaip.2016.09.012","article-title":"Vaccination in primary immunodeficiency disorders","volume":"4","author":"Sobh","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.vaccine.2025.126853_bb0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103705","article-title":"Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial","volume":"74","author":"Bergman","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2025.126853_bb0600","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.jaci.2021.08.016","article-title":"Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity","volume":"148","author":"Delmonte","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0605","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jaci.2017.12.980","article-title":"Update: vaccines in primary immunodeficiency","volume":"141","author":"Bonilla","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0610","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2217\/IMT.15.74","article-title":"Vaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalities","volume":"7","author":"Eibl","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/j.vaccine.2025.126853_bb0615","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jaci.2021.08.031","article-title":"Impaired memory B-cell response to the Pfizer-BioNTech COVID-19 vaccine in patients with common variable immunodeficiency","volume":"149","author":"Fernandez Salinas","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0620","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jaci.2021.05.029","article-title":"Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity","volume":"148","author":"Hagin","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0625","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.727850","article-title":"Humoral and cellular response following vaccination with the BNT162b2 mRNA COVID-19 vaccine in patients affected by primary Immunodeficiencies","volume":"12","author":"Amodio","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0630","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jaci.2021.11.022","article-title":"Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects","volume":"149","author":"Pham","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0635","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.974987","article-title":"Reactogenicity and immunogenicity of the second COVID-19 vaccination in patients with inborn errors of immunity or mannan-binding lectin deficiency","volume":"13","author":"G\u00f6schl","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0640","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/j.jaci.2022.04.002","article-title":"Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity","volume":"149","author":"van Leeuwen","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0645","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.895209","article-title":"Evaluation of humoral and cellular immune responses to the SARS-CoV-2 vaccine in patients with common variable immunodeficiency phenotype and patient receiving B-cell depletion therapy","volume":"13","author":"Antol\u00ed","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0650","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.3390\/cells10112915","article-title":"B cell response induced by SARS-CoV-2 infection is boosted by the BNT162b2 vaccine in primary antibody deficiencies","volume":"10","author":"Pulvirenti","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.vaccine.2025.126853_bb0655","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s10875-021-01133-0","article-title":"SARS-CoV-2 vaccine induced atypical immune responses in antibody defects: everybody does their best","volume":"41","author":"Salinas","year":"2021","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0660","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jaci.2023.10.009","article-title":"Emerging insights into atypical B cells in pediatric chronic infectious diseases and immune system disorders: T(o)-bet on control of B-cell immune activation","volume":"153","author":"Olivieri","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0665","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.907125","article-title":"Specific antibody and the T-cell response elicited by BNT162b2 boosting after two ChAdOx1 nCoV-19 in common variable immunodeficiency","volume":"13","author":"Goda","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0670","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.anai.2021.07.026","article-title":"Detection of neutralizing anti-severe acute respiratory syndrome coronavirus 2 antibodies in patients with common variable immunodeficiency after immunization with messenger RNA vaccines","volume":"127","author":"Romano","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0675","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.jaip.2022.03.017","article-title":"Response to severe acute respiratory syndrome coronavirus 2 initial series and additional dose vaccine in patients with predominant antibody deficiency","volume":"10","author":"Barmettler","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.vaccine.2025.126853_bb0680","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s10875-021-01174-5","article-title":"Immunogenicity of anti-SARS-CoV-2 vaccines in common variable immunodeficiency","volume":"42","author":"Arroyo-S\u00e1nchez","year":"2022","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103636","article-title":"Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy","volume":"73","author":"Gadani","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2025.126853_bb0690","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","article-title":"Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity","volume":"183","author":"Rydyznski Moderbacher","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2025.126853_bb0695","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1080\/13696998.2021.2002063","article-title":"Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2","volume":"24","author":"Di Fusco","year":"2021","journal-title":"J Med Econ"},{"key":"10.1016\/j.vaccine.2025.126853_bb0700","doi-asserted-by":"crossref","first-page":"1390022","DOI":"10.3389\/fimmu.2024.1390022","article-title":"Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program","volume":"15","author":"van Leeuwen","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0705","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.it.2023.11.002","article-title":"Modeling human immune responses to vaccination in vitro","volume":"45","author":"Morrocchi","year":"2024","journal-title":"Trends Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0710","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1001\/jamainternmed.2020.5084","article-title":"The exclusion of older persons from vaccine and treatment trials for coronavirus disease 2019-missing the target","volume":"180","author":"Helfand","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.vaccine.2025.126853_bb0715","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s40264-021-01131-6","article-title":"COVID-19 vaccination in pregnancy, Paediatrics, immunocompromised patients, and persons with history of allergy or prior SARS-CoV-2 infection: overview of current recommendations and pre- and post-marketing evidence for vaccine efficacy and safety","volume":"44","author":"Luxi","year":"2021","journal-title":"Drug Saf"},{"key":"10.1016\/j.vaccine.2025.126853_bb0720","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s40520-023-02380-4","article-title":"Exclusion of older adults and immunocompromised individuals in influenza, pneumococcal and COVID-19 vaccine trials before and after the COVID-19 pandemic","volume":"35","author":"Bukan","year":"2023","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.vaccine.2025.126853_bb0725","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1177\/1740774520945601","article-title":"When and how to include vulnerable subjects in clinical trials","volume":"17","author":"Wendler","year":"2020","journal-title":"Clin Trials"},{"key":"10.1016\/j.vaccine.2025.126853_bb0730","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.anai.2021.07.021","article-title":"Specific antibody response of patients with common variable immunodeficiency to BNT162b2 coronavirus disease 2019 vaccination","volume":"127","author":"Abo-Helo","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0735","doi-asserted-by":"crossref","first-page":"101","DOI":"10.15586\/aei.v50i3.583","article-title":"Easy approach to detect cell immunity to COVID vaccines in common variable immunodeficiency patients","volume":"50","author":"Barrios","year":"2022","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.vaccine.2025.126853_bb0740","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.jaip.2022.02.030","article-title":"Immunogenicity of a third COVID-19 messenger RNA vaccine dose in primary immunodeficiency disorder patients with functional B-cell defects","volume":"10","author":"Gernez","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.vaccine.2025.126853_bb0745","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s10875-022-01223-7","article-title":"Immunodeficiency Centre for Wales and Division of population medicine. COVID-19 vaccine uptake and efficacy in a National Immunodeficiency Cohort","volume":"42","author":"Ponsford","year":"2022","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.vaccine.2025.126853_bb0750","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s10875-022-01251-3","article-title":"Responses to SARS-CoV-2 vaccines of patients with common variable immune deficiencies and X-linked Agammaglobulinemia","volume":"42","author":"Carrabba","year":"2022","journal-title":"J Clin Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25001501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25001501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T21:39:08Z","timestamp":1745357948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25001501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":150,"alternative-id":["S0264410X25001501"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126853","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Shielding the immunocompromised: COVID-19 prevention strategies for patients with primary and secondary immunodeficiencies","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126853","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126853"}}